INmune Bio, Inc.

Contributing Author

Recent Articles by INmune Bio, Inc.

Oct-30	INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update INMB GlobeNewswire
Oct-23	INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 INMB GlobeNewswire
Oct-14	INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 INMB GlobeNewswire
Sep-29	INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal INMB GlobeNewswire
Sep-15	INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom at CGT Catapult INMB GlobeNewswire
Aug-07	INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes INMB GlobeNewswire
Aug-04	INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment INMB GlobeNewswire
Jul-31	INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th INMB GlobeNewswire
Jul-29	INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro Presented at the Alzheimer's Association International Conference INMB GlobeNewswire
Jul-24	INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at the Alzheimer's Association International Conference INMB GlobeNewswire
Jun-30	INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules INMB GlobeNewswire
Jun-30	INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimer's Disease INMB GlobeNewswire
Jun-27	INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules INMB GlobeNewswire
Jun-26	INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th INMB GlobeNewswire
Jun-10	XPro Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense INMB GlobeNewswire
May-14	INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference INMB GlobeNewswire
May-08	INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update INMB GlobeNewswire
May-05	INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th INMB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.